Supernus Pharmaceuticals, INC

Supernus Pharmaceuticals and Indivior Pharmaceuticals have agreed to combine in an all-stock merger of equals to create a leading U.S. biopharma company focused on CNS diseases.

Supernus Pharmaceuticals and Indivior Pharmaceuticals announced a merger of equals to create a diversified CNS biopharmaceutical leader with significant scale and projected annual cost synergies of at least $125 million.

Supernus Pharmaceuticals announced strong Q2 2026 results with a 32% revenue increase and raised full-year guidance, alongside a significant all-stock merger of equals with Indivior Pharmaceuticals.

Supernus Pharmaceuticals and Indivior Pharmaceuticals announced a merger of equals to create a diversified CNS biopharmaceutical company, Supernus, Inc., with expected annual revenues of $2.2 billion and $125 million in cost synergies.

Supernus Pharmaceuticals announced its second quarter 2026 financial results will be released after market close on August 4, 2026, with a conference call to follow.

Supernus Pharmaceuticals, Inc. reported the results of its annual meeting of stockholders held on June 18, 2026, detailing votes on director elections, executive compensation, auditor ratification, and equity incentive plan amendments.

Supernus Pharmaceuticals, Inc. reported a net loss of $58.4 million for the second quarter of 2026, impacted by a $54.9 million impairment charge, while total revenues increased 32% year-over-year.

Supernus Pharmaceuticals reported a significant net loss in Q3 2025, driven by the Sage Therapeutics acquisition and increased expenses, despite strong sales growth for Qelbree and the launch of ONAPGO.

Supernus Pharmaceuticals reports a significant drop in Q2 2025 net earnings and operating income, despite strong growth in key products and a major acquisition.

Supernus Pharmaceuticals' Q1 2025 results show increased revenue driven by Qelbree and GOCOVRI, offset by declines in other products, and the launch of ONAPGO.

Supernus Pharmaceuticals saw a significant increase in revenue and profitability in Q3 2024, driven by strong sales of Qelbree and GOCOVRI, while also advancing its pipeline with a resubmitted NDA for SPN-830.

Supernus Pharmaceuticals saw a significant increase in net product sales, particularly driven by Qelbree, in the second quarter of 2024, while also advancing its pipeline with a resubmitted NDA for SPN-830.

Supernus Pharmaceuticals reported a net loss of $38.6 million in 2025, driven by the Sage Therapeutics acquisition and increased expenses, despite growth in key product sales and new product launches.

Supernus Pharmaceuticals announces positive financial results for 2024 and FDA approval of ONAPGO for Parkinson's disease, while navigating generic competition and pipeline developments.

Supernus Pharmaceuticals' 2023 10-K filing details patent litigation, product updates, and financial performance, highlighting both challenges and progress in their CNS-focused business.

Indivior and Supernus Pharmaceuticals announce an all-stock merger of equals to create a leading U.S. biopharmaceutical company focused on central nervous system diseases.

Supernus Pharmaceuticals and Indivior Pharmaceuticals announced an all-stock merger of equals to create a leading U.S. biopharma company focused on central nervous system (CNS) diseases.

Supernus Pharmaceuticals and Indivior Pharmaceuticals announced a merger of equals to create a diversified CNS biopharmaceutical leader with significant scale and an expanded portfolio of 11 medicines.

Supernus Pharmaceuticals and Indivior Pharmaceuticals announced a merger of equals, creating a diversified CNS biopharmaceutical company with expected annual cost synergies of $125 million.

Jack A. Khattar, President, CEO and a Director of Supernus Pharmaceuticals, Inc., received 29,849 shares of common stock on July 29, 2026.

Timothy C Dec, Senior Vice-President & CFO of Supernus Pharmaceuticals, Inc., received 1,250 shares of common stock on July 29, 2026.

Supernus Pharmaceuticals schedules its 2026 Annual Meeting of Stockholders for June 18, 2026, to address director elections, executive compensation, and equity plan expansion.

Supernus Pharmaceuticals will hold its annual stockholders meeting virtually on June 16, 2025, to vote on director elections, executive compensation, auditor ratification, and a stockholder proposal.

Supernus Pharmaceuticals will hold its 2025 Annual Meeting of Stockholders virtually on June 16, 2025, to vote on director elections, executive compensation, and the ratification of its independent auditor.

Supernus Pharmaceuticals will hold its annual stockholders meeting virtually on June 14, 2024, to vote on director elections, executive compensation, auditor ratification, and an amendment to the equity incentive plan.

Supernus Pharmaceuticals will hold its 2024 Annual Meeting of Stockholders virtually on June 14, 2024, to vote on director elections, executive compensation, auditor ratification, and an equity incentive plan amendment.

Vanguard Capital Management has reported beneficial ownership of 5.03% of Supernus Pharmaceuticals Inc.'s common stock as of March 31, 2026.

Vanguard Portfolio Management has reported beneficial ownership of 5.66% of Supernus Pharmaceuticals Inc.'s common stock as of March 31, 2026.

The Vanguard Group reported 0% beneficial ownership in Supernus Pharmaceuticals Inc. following an internal realignment of its reporting structure.

Millennium Management LLC and affiliates have reported a 5.3% beneficial ownership stake in Supernus Pharmaceuticals, Inc. common stock.

Dimensional Fund Advisors LP has reported a 4.7% beneficial ownership stake in Supernus Pharmaceuticals Inc. common stock as of December 31, 2025.

Armistice Capital, LLC and Steven Boyd have reported a 5.06% beneficial ownership stake in Supernus Pharmaceuticals, Inc., totaling 2,836,000 shares.